Up next

Autoplay

Ajovy

2 Views • 08/29/25
Share
Side Effects
Side Effects
Subscribers
0

Ajovy prevents migraine headaches but apparently not as dramatically as anticipated. The pivotal study sponsored and funded by the pharmaceutical company Teva yielded unspectacular results against an inactive placebo. An editorial in the New England Journal of Medicine suggests therapy lacks a dramatic impact.

Among those suffering an average of 9 headache days a month, treatment reduced the number by about 3-4 days while an inactive placebo decreased it by 2.0-2.5 days. None of the currently available migraine preventive therapies were compared to Ajovy. Previous reports suggest these established drugs may be as effective as the newer agents.

During 2018 the FDA approved three expensive drugs for the prevention of migraine headaches. These injectables are not meant to treat the actual migraine, but rather to prevent them in people with at least 4 headaches a month.

By one measure of success – greater than 50% decrease in the number of migraine attacks or days of suffering – Ajovy does not rank well. Teva also planned to market Ajovy for chronic cluster headaches. Unfortunately their initial study failed to generate enthusiasm even in the company.

While the cash price approaches $700 a month, the company realizes the copay would be daunting. They offer significant inducements to transfer the financial burden of therapy solely to the insurance companies.

Show more
0 Comments sort Sort By